TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33523609

Group type: EXPERIMENTAL
Intervention: High-titer convalescent plasma
Number of subjects: 3082

Group type: EXPERIMENTAL
Intervention: Medium-titer convalescent plasma
Number of subjects: 3082

Group type: COMPARATOR
Intervention: Low-titer convalescent plasma
Number of subjects: 3082

Group type: EXPERIMENTAL
Intervention: High-titer convalescent plasma (non-mechanical ventilation)
Number of subjects: 3082

Group type: COMPARATOR
Intervention: Low-titer convalescent plasma (non-mechanical ventilation)
Number of subjects: 3082
Study: 33523760

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33524144

Group type: EXPERIMENTAL
Intervention: Ascending growth profile (n=82)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Intermediate growth profile (n=351)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Ascending growth profile
Number of subjects: 332

Group type: COMPARATOR
Intervention: Meeting intervention goals and exclusive breastfeeding for 3 months or more
Number of subjects: 332
Study: 33524306

Group type: EXPERIMENTAL
Intervention: Subjects with chronic bronchitis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 120
Study: 33524308

Group type: EXPERIMENTAL
Intervention: Uterine-sparing treatment
Number of subjects: 0
Study: 33524316

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33524399

Group type: EXPERIMENTAL
Intervention: Undernourished SEEM participants (n=52)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: EED transcriptome
Number of subjects: 416

Group type: COMPARATOR
Intervention: EED vs. Celiac Disease
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: EED epigenetic profile
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Duodenal coexpression modules
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Immune response genes
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Reduced circulating IGF-1
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Leptin and gene signature for lymphocyte activation and dysregulated lipid metabolism
Number of subjects: 416
Study: 33524462

Group type: EXPERIMENTAL
Intervention: AI-QTc on smartwatch single-lead electrocardiograms (SW-ECGs)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Manual QTc measurement on 12-lead ECG
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Comparison of AI-QTc and manual QTc
Number of subjects: 85
Study: 33524601

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg, day 1) and Anlotinib (12 mg, day 1-14) every 3 weeks
Number of subjects: 22
Study: 33524632

Group type: EXPERIMENTAL
Intervention: Oxford-12 score
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: HOOS components
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: FJS
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MCID for Oxford-12
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MCID for HOOS symptoms
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MCID for HOOS pain
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MCID for HOOS function
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MCID for HOOS sport
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MCID for HOOS quality of life
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Patient improvement ratings
Number of subjects: 123
Study: 33524990

Group type: EXPERIMENTAL
Intervention: BNT162b1 vaccine, one intramuscular dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine, one intramuscular dose
Number of subjects: 0
Study: 33526031

Group type: EXPERIMENTAL
Intervention: Highly challenging and progressive balance training for 10 weeks
Number of subjects: 12
Study: 33526148

Group type: EXPERIMENTAL
Intervention: Post stroke intervention program
Number of subjects: 470

Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 470
Study: 33526303

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 500
Study: 33526329

Group type: COMPARATOR
Intervention: RAMPART
Number of subjects: 3024

Group type: COMPARATOR
Intervention: PROSPER
Number of subjects: 3024

Group type: COMPARATOR
Intervention: CheckMate-914
Number of subjects: 3024

Group type: COMPARATOR
Intervention: Keynote-564
Number of subjects: 3024

Group type: COMPARATOR
Intervention: IMMotion-010
Number of subjects: 3024
Study: 33526480

Group type: EXPERIMENTAL
Intervention: Apollo Onyx delivery microcatheter
Number of subjects: 112
Study: 33526606

Group type: EXPERIMENTAL
Intervention: Bariatric surgery in younger adolescents (13-15 years)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Bariatric surgery in older adolescents (16-19 years)
Number of subjects: 242
Study: 33526820

Group type: EXPERIMENTAL
Intervention: Texture features in early-stage PD patients
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Texture features in late-stage PD patients
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108
Study: 33526918

Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host disease (cGVHD) evaluation
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Time from transplant to cGVHD evaluation
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Prior lines of systemic immunosuppressive therapy for cGVHD
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: C4 complement level
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 275
Study: 33527307

Group type: EXPERIMENTAL
Intervention: iCVMapper (CNN for ICV segmentation)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: VentMapper (CNN for ventricular segmentation)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: iCVMapper and VentMapper with CRF post-processing
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: iCVMapper and VentMapper
Number of subjects: 528
Study: 33527351

Group type: EXPERIMENTAL
Intervention: Bayesian dose regimen assessment method (DRtox)
Number of subjects: 0
Study: 33527447

Group type: EXPERIMENTAL
Intervention: Palatal (P) and Buccal (G) tissues
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: G and P tissues
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fibroblasts from all tissues
Number of subjects: 6
Study: 33527684

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization for infrainguinal PAD in CKD patients
Number of subjects: 3699
Study: 33527747

Group type: EXPERIMENTAL
Intervention: Leucite reinforced veneer material
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluorapatite glass-ceramic veneer material
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Y-TZP core zirconia ceramic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractal dimension measurements of flexure bars and FDPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical failure analysis of FDP replicates
Number of subjects: 0
Study: 33528045

Group type: EXPERIMENTAL
Intervention: Deficiency of OCRL protein in patients with Lowe syndrome
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control MKs transfected with OCRL-specific siRNA (siOCRL)
Number of subjects: 15
Study: 33528118

Group type: EXPERIMENTAL
Intervention: Recombinant subunit herpes zoster vaccine (RZV); 2 doses given 2-6 months apart.
Number of subjects: 23
Study: 33528286

Group type: EXPERIMENTAL
Intervention: Single-agent selinexor
Number of subjects: 0
Study: 33528371

Group type: EXPERIMENTAL
Intervention: mHealth-supported Family Strengthening Intervention for Early Childhood Development (FSI-ECD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard maternal and child health services
Number of subjects: 100
Study: 33528377

Group type: EXPERIMENTAL
Intervention: Web-based self-help program with personal guidance and automated email reminders
Number of subjects: 240

Group type: COMPARATOR
Intervention: Web-based self-help program without personal guidance and automated email reminders
Number of subjects: 240
Study: 33528378

Group type: EXPERIMENTAL
Intervention: HIV self-testing intervention alone
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: HIV self-testing combined with an mHealth intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: HIV testing standard of care
Number of subjects: 450
Study: 33528568

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-COVID-19 patients
Number of subjects: 38
Study: 33528632

Group type: EXPERIMENTAL
Intervention: Cemented arthroplasty in elderly patients (older than 66.5 years)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cemented arthroplasty in younger patients (younger than 66.5 years)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cemented arthroplasty in young patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cemented arthroplasty in elderly patients
Number of subjects: 25
Study: 33528675

Group type: EXPERIMENTAL
Intervention: Karaduman Chewing Performance Scale (KCPS) assessment by pediatric dentists
Number of subjects: 97
Study: 33528788

Group type: EXPERIMENTAL
Intervention: Postoperative nausea and vomiting management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early self-rated quality of life
Number of subjects: 0
Study: 33528792

Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (PR-FAM)
Number of subjects: 102
Study: 33528850

Group type: EXPERIMENTAL
Intervention: Joint Hypermobility Syndrome (JHS) in Functional Dyspepsia (FD)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nutrient tolerance in JHS-FD
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-JHS-FD
Number of subjects: 54
Study: 33528867

Group type: EXPERIMENTAL
Intervention: Inhibition of glycolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditioned medium from cancer-associated fibroblasts (CAFs)
Number of subjects: 0
Study: 33529058

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously once every 3 weeks for ≤ 24 months
Number of subjects: 165
Study: 33529226

Group type: EXPERIMENTAL
Intervention: Chronic TMD
Number of subjects: 45
Study: 33529485

Group type: EXPERIMENTAL
Intervention: Biomarkers for NAFLD (Steato-ELSA, Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), NAFLD-Liver Fat Score (NAFLD-LFS))
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Biomarkers for fibrosis (Fibrosis-4 score (FIB-4), Aspartate-to-Platelet Ratio Index (APRI), NAFLD Fibrosis Score (NFS))
Number of subjects: 674
Study: 33529989

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg intravenously once every 3 weeks, 2 cycles prior to surgery)
Number of subjects: 15
Study: 33530135

Group type: EXPERIMENTAL
Intervention: High food responsiveness
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low satiety responsiveness
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low food responsiveness
Number of subjects: 92
Study: 33530695

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Mental health service use
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Comorbid anxiety
Number of subjects: 160
Study: 33530929

Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Mindfulness (FFMQ total score)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Participants scoring 7 or more on the stress scale
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Average level of mindfulness
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Average score of stress at work
Number of subjects: 475
Study: 33530933

Group type: EXPERIMENTAL
Intervention: High sensitivity troponin T (hs-TNT)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: High sensitivity-C reactive protein (hs-CRP)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: N-terminal pro b-type natriuretic peptide (NT-proBNP)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein-cholesterol (HDL-C)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Combination of biomarkers with clinical risk factors
Number of subjects: 739
Study: 33531418

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment
Number of subjects: 0
Study: 33531437

Group type: EXPERIMENTAL
Intervention: Consistently sufficient levels of 25(OH)D
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Increasing levels or temporary drop in 25(OH)D
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Temporary drop in 25(OH)D
Number of subjects: 679

Group type: COMPARATOR
Intervention: Consistently deficient levels of 25(OH)D
Number of subjects: 679
Study: 33531438

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 62512

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 62512

Group type: COMPARATOR
Intervention: Never use (control)
Number of subjects: 62512
Study: 33531464

Group type: EXPERIMENTAL
Intervention: Estradiol challenge test (specific dosage and duration not provided)
Number of subjects: 0
Study: 33532807

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositivity testing
Number of subjects: 0
Study: 33533507

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg QD on Days 1-5
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GSK3640254 200 mg QD on Days 1-7
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg plus GSK3640254 200 mg QD on Days 1-7
Number of subjects: 16
Study: 33533547

Group type: EXPERIMENTAL
Intervention: 2019 anti-HCV antibody prevalence
Number of subjects: 2326

Group type: COMPARATOR
Intervention: 2012 anti-HCV antibody prevalence
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: 2019 HBsAg seropositivity
Number of subjects: 2326

Group type: COMPARATOR
Intervention: 2012 HBsAg seropositivity
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: HCV-viremic rate in 2019
Number of subjects: 2326

Group type: COMPARATOR
Intervention: HCV-viremic rate in 2012
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: HCV treatment rate in 2019
Number of subjects: 2326

Group type: COMPARATOR
Intervention: HCV treatment rate in 2012
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: Annual incidence of new HCV
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: HBsAg loss rate
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: New anti-HBc seropositivity rate
Number of subjects: 2326
Study: 33533663

Group type: EXPERIMENTAL
Intervention: Multi-national collaboration in the ROCK-ALS trial
Number of subjects: 0
Study: 33533729

Group type: EXPERIMENTAL
Intervention: XatJove Anoia mobile chat platform for health consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 0
Study: 33533986

Group type: EXPERIMENTAL
Intervention: Individualized management of breakthrough cancer pain (BTcP) therapy
Number of subjects: 93
Study: 33534046

Group type: COMPARATOR
Intervention: Locoregional surgery
Number of subjects: 1463
Study: 33534229

Group type: EXPERIMENTAL
Intervention: Primary breast cancer surgery within 12 months
Number of subjects: 1977

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 1977
Study: 33534266

Group type: EXPERIMENTAL
Intervention: COVID-19 patients admitted to Swedish ICUs
Number of subjects: 1563

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1563

Group type: EXPERIMENTAL
Intervention: SAPS III score
Number of subjects: 1563

Group type: EXPERIMENTAL
Intervention: Severe respiratory failure
Number of subjects: 1563

Group type: EXPERIMENTAL
Intervention: Specific COVID-19 pharmacotherapy
Number of subjects: 1563

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy
Number of subjects: 1563

Group type: EXPERIMENTAL
Intervention: Presence of comorbidities (except chronic lung disease)
Number of subjects: 1563
Study: 33534273

Group type: EXPERIMENTAL
Intervention: Walking fatigability (WF) group (n=20, EDSS: 4.16 ± 1.41)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Non-walking fatigability group (n=29, EDSS: 2.62 ± 1.94)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 49
Study: 33534419

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guided treatment
Number of subjects: 0
Study: 33534506

Group type: EXPERIMENTAL
Intervention: HEART Pathway implementation
Number of subjects: 3370
Study: 33534885

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine candidate (TAK-003)
Number of subjects: 0
Study: 33535013

Group type: EXPERIMENTAL
Intervention: Predictive low-glucose suspend (PLGS) system
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Insulin suspension during overnight basal up-titration
Number of subjects: 10
Study: 33535600

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibition as primary adjuvant therapy
Number of subjects: 1
Study: 33535772

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33535773

Group type: EXPERIMENTAL
Intervention: Investigator-reported (IR) triggers
Number of subjects: 2636

Group type: COMPARATOR
Intervention: Non-investigator-reported (non-IR) triggers
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: IR myocardial infarction events
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: IR bleeding events
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: IR stroke events
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: IR stent thrombosis events
Number of subjects: 2636
Study: 33535797

Group type: EXPERIMENTAL
Intervention: Pelvic pain severity
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Urinary symptom severity
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Urinary frequency
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Nonpelvic pain severity
Number of subjects: 370
Study: 33535799

Group type: EXPERIMENTAL
Intervention: Systematic Endoscopic Evaluation (cystoscopy and tissue sampling)
Number of subjects: 61
Study: 33536021

Group type: EXPERIMENTAL
Intervention: Intravenous selexipag
Number of subjects: 20
Study: 33536034

Group type: EXPERIMENTAL
Intervention: Upper-limb prosthesis
Number of subjects: 5

Group type: COMPARATOR
Intervention: Prosthetic simulator (Control group)
Number of subjects: 5
Study: 33536130

Group type: EXPERIMENTAL
Intervention: Amisulpride treatment for 4 weeks
Number of subjects: 387
Study: 33536430

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) with intravenous microbubble administration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS)
Number of subjects: 5
Study: 33536740

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light with Meibomian Gland Expression (IPL-MGX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meibomian Gland Expression (MGX)
Number of subjects: 20
Study: 33536791

Group type: EXPERIMENTAL
Intervention: Multi-professional medication reviews (MRs)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 369
Study: 33536998

Group type: EXPERIMENTAL
Intervention: Bicycle simulator training, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33537184

Group type: EXPERIMENTAL
Intervention: Healthy Primary Schools of the Future (HPSF)
Number of subjects: 1647

Group type: EXPERIMENTAL
Intervention: Physical Activity Schools (PAS)
Number of subjects: 1647

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1647
Study: 33537232

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for four cycles.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FLOT regimen for four cycles.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and relapse-free survival (RFS) outcomes after treatment.
Number of subjects: 10
Study: 33537339

Group type: EXPERIMENTAL
Intervention: Patients with Short Bowel Syndrome (SBS)
Number of subjects: 199
Study: 33537564

Group type: EXPERIMENTAL
Intervention: Lower dose subcutaneous sterile water injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous saline injection
Number of subjects: 0
Study: 33537575

Group type: EXPERIMENTAL
Intervention: High intensity smoking cessation intervention (n=42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Minimal contact control group (n=42)
Number of subjects: 84
Study: 33537757

Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy obese (MUHO) with T2D
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Obese men with T2D
Number of subjects: 112

Group type: COMPARATOR
Intervention: Metabolically healthy obese (MHO)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Metabolically unhealthy obese (MUHO) without T2D
Number of subjects: 112

Group type: COMPARATOR
Intervention: Obese men without T2D
Number of subjects: 112
Study: 33537947

Group type: EXPERIMENTAL
Intervention: Oral antithrombotic management patterns in patients with eGFR < 60 mL/min/1.73 m²
Number of subjects: 22380
Study: 33537956

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 23
Study: 33538517

Group type: EXPERIMENTAL
Intervention: Immediate-release carbidopa/levodopa (IR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled-release carbidopa/levodopa (CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa/entacapone (CLE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in levodopa equivalent daily dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parkinson's Disease Questionnaire mobility subscore
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schwab and England Activities of Daily Living Scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global composite outcome
Number of subjects: 0
Study: 33538649

Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) intervention called MOCT
Number of subjects: 60
Study: 33538688

Group type: EXPERIMENTAL
Intervention: Increased REM sleep time (200 min, 40% of total sleep time) and increased rapid eye movements density during REM sleep
Number of subjects: 1